Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Legislative bill overview

S 3797 seeks to prohibit the sale and distribution of tianeptine, a drug marketed under names like "gas station heroin," along with other potentially dangerous products not approved by the FDA. The bill would classify these substances as controlled or banned items, removing them from retail shelves and online marketplaces where they're currently sold without prescription.

Why is this important

Tianeptine is a antidepressant approved in some countries but not the FDA, yet it's widely sold in the U.S. through convenience stores and online retailers as a dietary supplement or nootropic. Users report opioid-like effects and withdrawal symptoms, creating a public health concern outside traditional pharmaceutical oversight. This bill addresses a regulatory gap where products with drug-like effects evade FDA control by exploiting supplement loopholes.

Potential points of contention

• Regulatory scope: Questions about whether Congress should expand federal prohibition powers versus allowing FDA administrative action, and how broadly "dangerous products" are defined
• Individual liberty vs. paternalism: Debate over government's role in restricting adult access to substances, especially those used off-label or in self-treatment
• Industry impact: Retailers and supplement manufacturers may oppose restrictions on currently legal sales, and businesses built around these products could face economic harm
• Enforcement challenges: Difficulty preventing online sales and international shipments, plus questions about resources needed for effective implementation